Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329397 | 0.89 | MAPT (0.39) | RAB9AMAOBLMNAALDH1A1GAA | |
| SCHEMBL4329400 | 0.89 | MAPT (0.39) | RAB9AMAOBLMNAALDH1A1GAA | |
| SCHEMBL4331693 | 0.89 | MAOB (0.41) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4331695 | 0.89 | MAOB (0.41) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4330708 | 0.88 | MAOB (0.40) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4330711 | 0.88 | MAOB (0.40) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4327449 | 0.88 | MAOB (0.44) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4327443 | 0.88 | MAOB (0.44) | L3MBTL1MAOBLMNAALDH1A1GAA | |
| SCHEMBL4338705 | 0.88 | MAOB (0.39) | MAOBALDH1A1GAA | |
| SCHEMBL4338700 | 0.88 | MAOB (0.39) | MAOBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | L3MBTL1 3722/4885CASP3 1550/4885POLB 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.